Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keh-Ming Lin

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Pharmacoepidemiology and Drug Safety|September 29, 2006
Usage of the claim database of national health insurance programme for analysis of cisapride-erythromycin co-medication in TaiwanChurn-Shiouh Gau, I-Shou Chang, Fe-Lin Lin Wu, et al.
Experimental and Molecular Pathology|April 25, 2003
The ADH3*2 and CYP2E1 c2 alleles increase the risk of alcoholism in Mexican American menTamiko Konishi, Maria Calvillo, Ai-She Leng, et al.
Pharmacogenomics|March 31, 2010
Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment responseMing-Hsien Tsai, Keh-Ming Lin, Mei-Chun Hsiao, et al.
International Journal of Methods in Psychiatric Research|February 22, 2005
Considering context, place and culture: the National Latino and Asian American StudyMargarita Alegria, David Takeuchi, Glorisa Canino, et al.
Journal of Human Genetics|December 11, 2012
OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: a cross sectional studyYu-Ting Chen, Hsiao-Hui Tsou, Hsiang-Wei Kuo, et al.
International Clinical Psychopharmacology|July 25, 2013
Comparison of escitalopram and paroxetine in the treatment of major depressive disorderHuang-Li Lin, Ya-Ting Hsu, Chia-Yih Liu, et al.
Journal of Clinical Psychopharmacology|February 15, 2014
The association of genetic polymorphisms in the κ-opioid receptor 1 gene with body weight, alcohol use, and withdrawal symptoms in patients with methadone maintenanceSheng-Chang Wang, Hsiao-Hui Tsou, Ren-Hua Chung, et al.
Pharmacogenomics|December 3, 2010
CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetineKeh-Ming Lin, Hsiao-Hui Tsou, I-Ju Tsai, et al.
Pharmacogenomics|September 10, 2011
Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patientsChia-Hui Chen, Sheng-Chang Wang, Hsiao-Hui Tsou, et al.
Pharmacogenetics and Genomics|September 23, 2010
ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatmentKeh-Ming Lin, Yen-Feng Chiu, I-Ju Tsai, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Pharmacoepidemiology and Drug Safety|September 29, 2006
Usage of the claim database of national health insurance programme for analysis of cisapride-erythromycin co-medication in TaiwanChurn-Shiouh Gau, I-Shou Chang, Fe-Lin Lin Wu, et al.
Experimental and Molecular Pathology|April 25, 2003
The ADH3*2 and CYP2E1 c2 alleles increase the risk of alcoholism in Mexican American menTamiko Konishi, Maria Calvillo, Ai-She Leng, et al.
Pharmacogenomics|March 31, 2010
Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment responseMing-Hsien Tsai, Keh-Ming Lin, Mei-Chun Hsiao, et al.
International Journal of Methods in Psychiatric Research|February 22, 2005
Considering context, place and culture: the National Latino and Asian American StudyMargarita Alegria, David Takeuchi, Glorisa Canino, et al.
Journal of Human Genetics|December 11, 2012
OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: a cross sectional studyYu-Ting Chen, Hsiao-Hui Tsou, Hsiang-Wei Kuo, et al.
International Clinical Psychopharmacology|July 25, 2013
Comparison of escitalopram and paroxetine in the treatment of major depressive disorderHuang-Li Lin, Ya-Ting Hsu, Chia-Yih Liu, et al.
Journal of Clinical Psychopharmacology|February 15, 2014
The association of genetic polymorphisms in the κ-opioid receptor 1 gene with body weight, alcohol use, and withdrawal symptoms in patients with methadone maintenanceSheng-Chang Wang, Hsiao-Hui Tsou, Ren-Hua Chung, et al.
Pharmacogenomics|December 3, 2010
CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetineKeh-Ming Lin, Hsiao-Hui Tsou, I-Ju Tsai, et al.
Pharmacogenomics|September 10, 2011
Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patientsChia-Hui Chen, Sheng-Chang Wang, Hsiao-Hui Tsou, et al.
Pharmacogenetics and Genomics|September 23, 2010
ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatmentKeh-Ming Lin, Yen-Feng Chiu, I-Ju Tsai, et al.
Pageof 6